Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

- PMLiVE

Two blood cancer drugs among CHMP recommendations

Five new drugs, including Janssen’s Imbruvica and Gilead’s Zydelig, backed for use in Europe

- PMLiVE

Neupogen will be first biologic on FDA biosimilars pathway

US regulator will review Novartis’  version of Amgen's Neupogen (filgrastim) over the coming months

- PMLiVE

BMJ accuses Boehringer of withholding Pradaxa data

Claims current FDA recommendation for anticoagulant may be flawed

- PMLiVE

Boehringer goes on PR offensive over Pradaxa report

Takes to social media to defend its position on the anticoagulant ahead of tonight's Channel 4 news report

- PMLiVE

Neuway appoints Boehringer’s Baiker to board

He has 25 years’ experience at German pharma company

ABPI London offices

ABPI and BIA to support understanding of biosimilars

Trade bodies work together on communication materials for prescribers

- PMLiVE

Eisai’s Bose to join Boehringer

He becomes head of global marketing for oncology

dengue fever mosquito

Sanofi’s dengue vaccine could debut in 2015

End in sight after 20-year wait for first effective vaccine

Free Thinking: Biosimilars: Friend or foe to healthcare?

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.

Research Partnership

- PMLiVE

FDA to review Sanofi’s Lantus successor

Decision on company’s next generation insulin Toujeo expected early next year

- PMLiVE

The moving parts of orphan drug development

Tackling rare diseases requires high levels of cooperation, regulatory support and a determination to succeed

- PMLiVE

Amgen and Boehringer drugs win FDA breakthrough status

Leukaemia drug and Pradaxa antidote will benefit from accelerated regulatory processes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links